Dana. you, Thank
member listening alike. patients, standard filing committed paltusotine. and now endocrinology an treatment the Acromegaly conferences to indication on establish many the health health years, of care for the a with Crinetics been care new of We're from and many sessions opportunity community. providers has paltusotine for in practitioners in verge For learned medical countless is first of payers. acromegaly the participated a both of and the care We patients NDA,
laying preparation fully launch for pipeline. that as in foundation the syndrome including other of drug candidates leveraged our organization carcinoid are indications, integrated well a can be future activities Our as
to not molecules has is any acromegaly in established Our marketplace, the which overarching disrupt decade. seen strategy over a new
infrastructure commercial differentiated, our market and clinically oral to differentiated a bringing are with We services. support medication once-daily
by Our commercial underlying pillars. X guided is strategy
extending therapy. practitioners; streamlining patients; partnership care empowering First, second, and access third, Crinetics health with to
partnership extending The first with pillar the community. our endocrinology is
of be We base into approximately a the for of vast launching who XXX prescriptions. prescriber will care practitioners health concentrated responsible majority are
be other XX small to a the sales XX can with These representatives, across affairs. sales reached with of activities in medical organization, providers force conjunction approximately including
multiple conducted we and lines of relationships of burden the patient building prescribers, disconnect are what standard actually what a As care. our with with awareness their and is patients the associated theme we between We've research, current common market physicians and deepen one experience. of experience perceive
endocrinologists acromegaly we symptomatically. believe and their are example, pharmacotherapy that biochemically patients on well-controlled, For of found X/X
However, found acromegaly in our patient surveys, that symptoms. patients report of breakthrough we XX%
Now treatment appointments. these monthly that detrimental indicated lives, are that have mention Patients end their can breakthrough of symptoms and the may this to symptoms treatment during be reemerge their not but toward often physician cycle. patients the burden their
asking information, aren't not aren't and addressed. the disconnect doctors being if So is this volunteering patients
We Health are are care. dialogue aware complete And occur pain the somatostatin option receptor an the at and symptoms the and the patients. always limitations their Crinetics the with of injection seeking patient current We practitioners providing today, can help including subcutaneous they at patients' for bridge addresses the and disconnect into experience. to intramuscular the best want experience, ligand frequent don't visibility deep care breakthrough associated treatment their that practitioners that health the standard of always end and of to cycle. dedicated the challenges more and become have of injections care
it treatment may as option today's designed limitations the address of to was believe standard better of We paltusotine a provide patients care. for
campaign includes site see GI recently Our site X,XXX disease injection acromegalytruth.com, on endocrinologists reactions, Slide which on so for can commercial impact than team side X. and Acromegalytruth.com interacted have emotional perspectives effects, has treatment. More SRLs, including acromegaly, of from this already symptoms treating injectable patients our you launched awareness with providers breakthrough with far. patients
diary, care help program symptom of well understand used In of paltusotine, addition, beyond the secondary the Phase health which benefits the was PATHFNDR endpoints we believe that III one biochemical acromegaly positive data the practitioners control. will from clinical go in which
from understand fact, the shared In at have their already data hope we June. Endo past this patients. diary We of impact some this the will transformative of data symptom help acromegaly potential for paltusotine this physicians
academic pituitary key treatment in with strong relationships centers. opinion have the already We leaders
we we've execution, deepening of managing commercial our in day are an of initial clinical patients the are who example looking our leader thought the in community another to day To assembled with end, As with relationship liaisons team in endocrinologists endocrinologists are setting. expand that relationships our out. and who field
pillar is to patients plan second The better their our ask care commercial symptoms. improved control and empowering of for of
to patients vital year is to targeted we approved. goal role realize control and diagnosis, be managing empower their ask care with The their seeking To next the recognize symptoms campaign towards the want this help patients an in play optimal for We better treatment possible. awareness disease paltusotine to acromegaly. once burden advocating their patients acromegaly practitioner that disease treatment. launch lower health of patients for plan to expanded end, and their Ultimately, may we
in with acromegaly has early team been clinical As organizations patient Dana development. patient advocacy mentioned, since engaging our the
patient to continuing are of patients. the we to addressing our are community the with ensure We relationship needs strengthen
our best-in-class for The in patient of onboarded. payer ensure our account optimal national therapy. is to to interactions commercial third all is team The plan place access pillar responsible and
initial discussions from have the We has those majority meetings had payer top country in been and payers feedback covering and of encouraging. the government commercial lives the advisory with
process. support designed the finalizing in patient and dispensing being our practices best prescribing, reimbursement with to a reimbursement streamline is current processes. close the discussions are differentiated research develop and center on support market ongoing help the highly center and to patients based We gaps This
details to finalized earnings at We also our sharing channel. call. have look We next our distribution more forward
his a as for and with [ much built medical and endocrinologist who Cathie addition scientific to has an including in Sanofi foundation team experienced treating and throughout Bob such acromegaly Janssen, led We've those robust organizations commercial community. our medical launch, affairs has dedicated medical of functions career at to affairs the the patients, Amgen. other engaging successful is establishing hired In discussions Dr. ],
who to conclusion, approval. ensure our we our to data execute the position to clinical continues control, strategy unique been Crinetics have to demonstrate We the patient the position In launch differentiated in overall profile control, to care know what to us highly evolution system. is physicians are puts following a in treat paltusotine patients, dimensions, across generated that biochemical tolerability experience. that them important date to the best including health The symptom and multiple and a
well. of proposition which of serves we in believe value And the paltusotine, each these constituencies
expected our acromegaly months, potential believe commercial XXXX, therapy. launch to coming the our Over of paltusotine share updates team we and I'm leading leading will up along implement with patients continue to way. this to strategy the excited to in the launch I be and transformative in for commercial the
prepared a We as well will pharmaceutical the for laying are future in for fully that as the integrated indications company be products pipeline. other foundation Crinetics paltusotine
to hand now will over review I to that, the Marc With it financials.